Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Krystal Biotech Inc Market Cap
From what 1 stock analysts predict, the share price for Krystal Biotech Inc (KRYS) might increase by 17% in the next year. This is based on a 12-month average estimation for KRYS. Price targets go from $193 to $221. The majority of stock analysts believe KRYS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned KRYS 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Krystal Biotech Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KRYS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of KRYS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Dae Gon Ha Stifel | Buy | $220 | Maintains | Sep 11, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Aug 29, 2024 | |
| Joseph Pantginis HC Wainwright & Co. | Buy | $221 | Reiterates | Aug 29, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $221 | Maintains | Aug 28, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $206 | Maintains | Aug 12, 2024 |
| Yigal Nochomovitz Citigroup | Neutral | $204 | Downgrade | Aug 6, 2024 |
| Geulah Livshits Chardan Capital | Buy | $208 | Maintains | Aug 5, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $200 | Reiterates | Aug 5, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $200 | Reiterates | May 8, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $200 | Reiterates | May 6, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $200 | Reiterates | Apr 22, 2024 |
| Dae Gon Ha Stifel | Buy | $204 | Reiterates | Apr 16, 2024 |
| Yigal Nochomovitz Citigroup | Buy | $195 | Maintains | Feb 27, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $175 | Maintains | Feb 27, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $180 | Maintains | Dec 13, 2023 |
| Andrea Tan Goldman Sachs | Buy | $160 | Initiates | Nov 20, 2023 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $160 | Reiterates | Nov 7, 2023 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $160 | Initiates | Oct 24, 2023 |
| Carly Kenselaar Citigroup | Buy | $160 | Initiates | Oct 12, 2023 |
| Caroline Palomeque Berenberg | Buy | $154 | Initiates | Sep 7, 2023 |
When did it IPO
2017
Staff Count
229
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Market Cap
$5.09B
In 2023, KRYS generated $50.7M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KRYS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 18 Sep 2024
Sentiment - POSITIVE
Source - Investors Business Daily
Summary - Krystal Biotech has achieved an average annual gain of 256% since its IPO, indicating strong performance in the market.
Why It Matters - Krystal Biotech's annual average return of 256% since its IPO signifies strong growth potential, attracting attention from investors seeking high-yield opportunities.
Fri, 13 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, with CEO Krish S. Krishnan hosting a fireside chat and investor meetings.
Why It Matters - Krystal Biotech's participation in the healthcare conference signals potential updates on company developments, which could influence stock performance and investor sentiment.
Fri, 06 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Krystal Biotech, Inc. (NASDAQ: KRYS) will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 12:30 pm ET, and will hold investor meetings.
Why It Matters - Krystal Biotech's participation in a major investment conference highlights its visibility and engagement with investors, potentially impacting stock performance and investor sentiment.
Tue, 03 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Krystal Biotech (KRYS) shares are rising, supported by strong earnings estimate revisions, suggesting potential continued growth in the near term.
Why It Matters - Rising earnings estimate revisions for Krystal Biotech suggest improved financial performance, potentially driving share price appreciation and attracting investor interest.
Fri, 30 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - KRYS has increased 21.9% over the past three months, driven by strong demand for its new drug Vyjuvek and positive developments in its pipeline.
Why It Matters - KRYS's 21.9% gain reflects strong market confidence driven by Vyjuvek's success and positive pipeline developments, indicating potential future revenue growth and investment returns.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Krystal Biotech, Inc. (NASDAQ: KRYS) will hold its Q2 2024 Earnings Conference Call on August 5, 2024, at 8:30 AM ET, featuring key executives and financial analysts.
Why It Matters - Krystal Biotech's upcoming earnings call will provide insights into its financial performance and strategic direction, influencing market sentiment and stock valuation.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
